Target specificity and off-target effects as determinants of cancer drug efficacy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 3, 2008, Pages 273-280

  Shoshan, Maria C ^a   Linder, Stig ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anticancer drugs; Off target effects; Targeted therapies; Tyrosine kinase inhibitors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DAUNORUBICIN; DEPSIPEPTIDE; DOXORUBICIN; ELLIPTICINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; NVP AEW 541; PACLITAXEL; PODOPHYLLOTOXIN; PROTEASOME; RADICICOL; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; TRICHOSTATIN A; UNINDEXED DRUG; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOMA; CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL TRIAL; COLON CARCINOMA; DNA ADDUCT; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TARGETING; FIBROSARCOMA; HUMAN; KIDNEY CARCINOMA; LIPID PEROXIDATION; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MULTIPLE MYELOMA; NEPHROTOXICITY; OTOTOXICITY; OVARY CANCER; PROSTATE CARCINOMA; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; SURVIVAL RATE; TESTIS CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; SENSITIVITY AND SPECIFICITY;

EID: 42949125866     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.3.273     Document Type: Review

References (74)

1. Waters CM, Littlewood TD, Hancock DC, et al. c-myc protein expression in untransformed fibroblasts. Oncogene 1991;6(5):797-805
2. Scheele JS, Rhee JM, Boss GR. Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: comparison of parental and Ras-overproducing NIH 3T3 fibroblasts. Proc Natl Acad Sci USA 1995;92(4):1097-100
3. Schilling M, Maiwald T, Bohl S, et al. Computational processing and error reduction strategies for standardized quantitative data in biological networks. FEBS J 2005;272(24):6400-11
4. Osawa S, Betz G, Hall PF. Role of actin in the responses of adrenal cells to ACTH and cyclic AMP: inhibition by DNase I. J Cell Biol 1984;99(4 Pt 1):1335-42
5. Nadal-Ginard B. Regulation of lactate dehydrogenase levels in the mouse. J Biol Chem 1978;253(1):170-7
6. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26(4):178-82
7. Walczak CE. Microtubule dynamics and tubulin interacting proteins. Curr Opin Cell Biol 2000;12(1):52-6
8. Islam MN, Iskander MN. Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem 2004;4(10):1077-4
9. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351(Pt 1):95-105
10. Drevs J, Medinger M, Schmidt-Gersbach C, et al. Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr Drug Targets 2003;4(2):113-21
11. Eastman A. Mechanisms of resistance to cisplatin. Cancer Treat Res 1991;57:233-49
12. Peleg-Shulman T, Najajreh Y, Gibson D. Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles. J Inorg Biochem 2002;91(1):306-11
13. Hannemann J, Baumann K. Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers. Toxicology 1988;51(2-3):119-32
14. Baek SM, Kwon CH, Kim JH, et al. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 2003;142(3):178-86
15. Kim YK, Jung JS, Lee SH, Kim YW. Effects of antioxidants and Ca2+ in cisplatin-induced cell injury in rabbit renal cortical slices. Toxicol Appl Pharmacol 1997;146(2):261-9
16. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999;31(4):971-97
17. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003;278(11):9100-6
18. Berndtsson M, Hagg M, Panaretakis T, et al. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2007;120(1):175-80
19. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56(2):185-229
20. Doroshow JH, Synold TW, Somlo G, et al. Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 2001;97(9):2839-45
21. Hägg M, Berndtsson M, Mandic A, et al. Induction of endoplasmic reticulum stress by ellipticine plant alkaloids. Mol Cancer Ther 2004;3(4):489-97
22. Peng Y, Li C, Chen L, et al. Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003;22(29):4478-87
23. Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S. Distinct pathways for stimulation of cytochrome c release by etoposide. J Biol Chem 2000;275(42):32438-43
24. England K, O'Driscoll C, Cotter TG. Carbonylation of glycolytic proteins is a key response to drug-induced oxidative stress and apoptosis. Cell Death Differ 2004;11(3):252-60
25. Andre N, Braguer D, Brasseur G, et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 2000;60(19):5349-53
26. Kidd JF, Pilkington MF, Schell MJ, et al. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem 2002;277(8):6504-10
27. Hajnoczky G, Lin C, Thomas AP. Luminal communication between intracellular calcium stores modulated by GTP and the cytoskeleton. J Biol Chem 1994;269(14):10280-7
28. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20(1):325-34
29. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8(10):3034-8
30. Nygren P, Larsson R. Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med 2003;253(1):46-75
31. Kaklamani V, O'Regan EM. New targeted therapies in breast cancer. Semin Oncol 2004;31(2 Suppl 4):20-5
32. Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000;60 Suppl 1:33-40
33. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11(14):1911-4
34. Wilkinson E. Surprise phase III failure for ZD1839. Lancet Oncol 2002;3(10):583
35. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
36. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500
37. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
38. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23(25):5892-9
39. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5(3):231-9
40. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990;10(2):464-73
41. Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994;14(6):3604-12
42. Manara MC, Landuzzi L Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007;13(4):1322-30
43. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007;26(25):3637-43
44. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;13 Suppl 1:S125-35
45. Chiosis G, Timaul MN, Lucas B, et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp9O causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001;8(3):289-99
46. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003;9(17):6316-25
47. Caravita T, de Fabritiis P, Palumbo A, et al. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 2006;3(7):374-87
48. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24(22):9695-704
49. Yeung BH, Huang DC, Sinicrope FA. PS-341 (Bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 2006;281(17):11923-32
50. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005;2(3):150-7
51. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004;91:137-68
52. Butler LM, Zhou X, Xu WS, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 2002;99(18):11700-5
53. Glaser KB, Staver MJ, Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2(2):151-63
54. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97(18):10014-9
55. Gui CY, Ngo L, Xu WS, et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004;101(5):1241-6
56. Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007;13(13):3765-70
57. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002;8(25):2255-7
58. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
59. Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005;280(42):35217-27
60. Rahmani M, Davis EM, Crabtree TR, et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 2007;27:5499-513
61. O'Farrell AM, Abrams TJ, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101(9):3597-605
62. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2(10):1011-21
63. Loike JD, Brewer CF, Sternlicht H, et al. Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Res 1978;38(9):2688-93
64. Girnita A, Girnita L, del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64(1):236-42
65. Paul AT, Gohil VM, Bhutani KK. Modulating TNF-alpha signaling with natural products. Drug Discov Today 2006;11(15-16):725-32
66. Erkel G, Anke T, Sterner O. Inhibition of NF-kappa B activation by panepoxydone. Biochem Biophys Res Commun 1996;226(1):214-21
67. Gehrt A, Erkel G, Anke T, Sterner O. Cycloepoxydon, 1-hydroxy-2-hydroxymethyl-3-pent-1-enylbenzene and 1-hydroxy-2-hydroxymethyl-3-pent-1,3-dienylbenzene, new inhibitors of eukaryotic signal transduction. J Antibiot (Tokyo) 1998;51(5):455-63
68. Pahl HL, Krauss B, Schulze-Osthoff K, et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaβ. J Exp Med 1996;183(4):1829-40
69. Xia D, Wang F, Parmely MJ. Inhibition of nuclear factor-kappaβ activation in mouse macrophages and the RAW 264.7 cell line by a synthetic adenyl carbocyclic nucleoside. Biochem Pharmacol 2000;60(5):717-27
70. Shoji S, Furuishi K, Ogata A, et al. An allosteric drug, o,o′-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kappa β. Biochem Biophys Res Commun 1998;249(3):745-53
71. Ariga A, Namekawa J, Matsumoto N, et al. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002;277(27):24625-30
72. Linder S, Shoshan MC, Gupta RS. Picropodophyllotoxin or podophyllotoxin does not induce cell death via insulin-like growth factor-I receptor. Cancer Res 2007;67(6):2899
73. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-5
74. Kamb A. What's wrong with our cancer models? Nat Rev Drug Discov 2005;4(2):161-5